Modality
Vaccine
MOA
STINGag
Target
FcRn
Pathway
Angiogenesis
CRC
Development Pipeline
Preclinical
~Jan 2021
→ ~Apr 2022
Phase 1
Jul 2022
→ May 2030
Phase 1Current
NCT05635350
696 pts·CRC
2025-06→2030-05·Recruiting
NCT08966725
2,262 pts·CRC
2022-07→2029-02·Recruiting
2,958 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-02-172.9y awayInterim· CRC
2030-05-284.2y awayInterim· CRC
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P1
Recruit…
P1
Recruit…
Catalysts
Interim
2029-02-17 · 2.9y away
CRC
Interim
2030-05-28 · 4.2y away
CRC
Recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05635350 | Phase 1 | CRC | Recruiting | 696 | PANSS |
| NCT08966725 | Phase 1 | CRC | Recruiting | 2262 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| RHH-5389 | Roche | Preclinical | RET | |
| Gelinaritide | AbbVie | Preclinical | FcRn | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| Talalemzoparlimab | Gilead Sciences | Phase 1 | FcRn | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| Sovafutibatinib | Moderna | Approved | FcRn |